Compare · GBIO vs TIL
GBIO vs TIL
Side-by-side comparison of Generation Bio Co. (GBIO) and Instil Bio Inc. (TIL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. GBIO focuses on Biotechnology: Pharmaceutical Preparations, while TIL focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- GBIO is the larger of the two at $347.7M, about 6.4x TIL ($54.4M).
- Over the past year, GBIO is up 26.4% and TIL is down 78.6% - GBIO leads by 105.0 points.
- TIL has more recent analyst coverage (10 ratings vs 8 for GBIO).
- Company
- Generation Bio Co.
- Instil Bio Inc.
- Price
- $5.37-6.20%
- $8.00-2.62%
- Market cap
- $347.7M
- $54.4M
- 1M return
- -1.10%
- -2.14%
- 1Y return
- +26.35%
- -78.61%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2021
- News (4w)
- 0
- 0
- Recent ratings
- 8
- 10
Generation Bio Co.
Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Instil Bio Inc.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.
Latest GBIO
- SEC Form 15-12G filed by Generation Bio Co.
- Amendment: SEC Form SCHEDULE 13G/A filed by Generation Bio Co.
- Amendment: SEC Form SCHEDULE 13G/A filed by Generation Bio Co.
- SEC Form EFFECT filed by Generation Bio Co.
- SEC Form 4 filed by Large owner Atlas Venture Fund X, L.P.
- Director Stehman-Breen Catherine closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Rhodes Jason P
- Director Rowland Charles A Jr closing all direct ownership in the company (SEC Form 4)
- Director Quinn Anthony G. closing all direct ownership in the company (SEC Form 4)
- Director Nicholson Donald William closing all direct ownership in the company (SEC Form 4)
Latest TIL
- SEC Form 10-Q filed by Instil Bio Inc.
- Instil Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form DEFA14A filed by Instil Bio Inc.
- SEC Form DEF 14A filed by Instil Bio Inc.
- Instil Bio Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- SEC Form S-8 filed by Instil Bio Inc.
- SEC Form 10-K filed by Instil Bio Inc.
- Instil Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update